GLP-1 Drug Shows Promise in Slowing Alzheimer's

Liraglutide, a diabetes medication, may reduce brain inflammation and preserve brain volume in early-stage Alzheimer's patients.

Study finds liraglutide slows cognitive decline by 18% over one year in mild Alzheimer's patients.
Liraglutide reduces brain inflammation and improves insulin resistance, according to researchers.
Trial involved 204 patients, with significant preservation of brain volume observed.
Common side effects included gastrointestinal issues like nausea.
Larger trials are underway to confirm these findings and explore further benefits.